David R. Bauer
Lawyers
Filters
Personalis, Inc. $150 million stock offering
We advised the underwriters on the equity offering
Precigen $129 million common stock offering
We advised the underwriters in connection with the SEC-registered equity offering
CytomX Therapeutics $100 million follow-on offering
We advised the joint book-running managers in connection with the equity offering
Editas Medicine $231 million stock offering
We advised the joint book-running managers in connection with the equity offering
Affimed $115 million offering of shares
We advised the underwriters on the public equity offering
Generation Bio $225.4 million stock offering
We advised the underwriters on the public equity offering
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
NGM Biopharmaceuticals $125 million follow-on offering
We advised the joint book-running managers on the public equity offering
Gamida Cell $75 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $75 million SEC-registered follow-on offering of 9,343,750 ordinary shares of Gamida Cell Ltd, which…
BeiGene $340 million secondary offering
Davis Polk advised the underwriter in connection with the $340 million SEC-registered offering of 1,511,546 American depositary shares of BeiGene, Ltd. by certain existing ADS holders. The…